Please login to the form below

Not currently logged in
Email:
Password:

Intercept Pharmaceuticals

This page shows the latest Intercept Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Merck enters agreement with Hanmi for investigational NASH drug

Merck enters agreement with Hanmi for investigational NASH drug

Intercept Pharmaceuticals is awaiting a US Food and Drug Administration (FDA) review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again

Latest news

  • Genfit scraps phase 3 trial of experimental NASH drug Genfit scraps phase 3 trial of experimental NASH drug

    Another potential competitor – Intercept Pharmaceuticals – is still awaiting an FDA review of its obeticholic acid drug Ocaliva in NASH after a number of delays, first in January and then again in

  • FDA delays decision on Intercept's NASH drug by three months FDA delays decision on Intercept's NASH drug by three months

    Action date pushed back to 26 June. The US Food and Drug Administration (FDA) has pushed back the date on which it is due to decide whether to approve Intercept Pharmaceuticals’ ... additional information provided in response to FDA requests,”

  • Intercept gets EU nod for rare liver disease therapy Intercept gets EU nod for rare liver disease therapy

    Ocaliva approved as a combination treatment for primary biliary cholangitis. Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both sides of the ... Intercept launched Ocaliva in the US

  • Gilead chalks up trial success for new NASH drug Gilead chalks up trial success for new NASH drug

    The company is vying with rivals such as Allergan and Intercept Pharmaceuticals in its pursuit of the NASH market. . ... Allergan has been building a pipeline of candidates through a series of bolt-on acquisitions including Akarna Therapeutics and

  • Takeda enlists GE's aid to tackle liver fibrosis epidemic Takeda enlists GE's aid to tackle liver fibrosis epidemic

    Takeda is playing catch-up in the liver fibrosis race, with rivals such as Gilead Sciences, Intercept Pharmaceuticals, Galectin Therapeutics and Genfit already having compounds in the clinic. ... Gilead's simtuzumab is in phase II testing in NASH, while

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Simon Doyle joins STEM Simon Doyle joins STEM

    Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help

  • Glenn Sblendorio to retire as president of The Medicines Company Glenn Sblendorio to retire as president of The Medicines Company

    He has over 20 years of experience in the pharmaceutical industry and prior to joining The Medicines Company held senior managing and financial positions at Eyetech Pharmaceuticals and MPM Capital Advisors. ... He currently serves as a director at Amicus

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....

Infographics